Last reviewed · How we verify
ganagliflozin
ganagliflozin is a Small molecule drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. It is currently FDA-approved.
Ganagliflozin is an SGLT2 inhibitor used to treat type 2 diabetes, and it has also been studied for its potential to slow the progression of kidney disease in people with type 2 diabetes and chronic kidney disease. It is approved in China for the treatment of type 2 diabetes.
At a glance
| Generic name | ganagliflozin |
|---|---|
| Sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control (PHASE4)
- Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ganagliflozin CI brief — competitive landscape report
- ganagliflozin updates RSS · CI watch RSS
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about ganagliflozin
What is ganagliflozin?
Who makes ganagliflozin?
What development phase is ganagliflozin in?
Related
- Manufacturer: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing